Form D · Other Technology
Bluejay Therapeutics, Inc.
San Mateo, CA · CIK 0001868267
Offering snapshot reported May 10, 2024 · SEC filing
- Reported sold
- $182M Offering amount: $182M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 1, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 10, 2024 | Initial | $181,999,946 | No comparison | 19 | SEC filing |
| Aug 16, 2022 | Initial | $20,499,976 | No comparison | 9 | SEC filing |
| Jun 18, 2021 | Initial | $19,239,990 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-512955
Source: Form D, filed May 10, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Wen Chen | Director |
| Keting Chu | Director, Executive |
| Dan Estes | Director |
| Nancy Hong | Director |
| Ting Jia | Director |
| Pascal Krotee | Director |
| Alon Lazarus | Director |
| Jianqing Li | Director |
| William J. Rutter | Director |
| Dajun Yang | Director |
Issuer details
Industry: Other Technology (See others in industry)
Address:
400 Concar Drive, Suite 3 101
San Mateo, CA, 94402
San Mateo, CA, 94402